Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
AKBA · Nasdaq · United States · Pharmaceutical Preparations
In shortAkebia Therapeutics, Inc. is loss-making, generates cash and holds more cash than debt, with revenue growing (+47.5% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 9.9% | 50/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -2.3% | 11/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | – | n/a |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 23.0% | 100/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.55× | 63/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 1.48× | 29/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | – | n/a |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -12.49 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 28.7% | 100/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 1 of 5 | 0/100 |
Weight in the score: 20%
| Profitable years (last 5) | 0 of 5 | 0/100 |
|---|---|---|
| Years of revenue decline (last 5) | 3 of 5 | 0/100 |
| Revenue growth volatility | 38.5% | 0/100 |
| Operating margin volatility | 50.5% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | -6.9% | 0/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 212 | 292 | 195 | 160 | 236 |
| Cost of revenue | 151 | 86 | 74 | 63 | 39 |
| Gross profit | 61 | 207 | 120 | 97 | 197 |
| Research & development | 148 | 130 | 63 | 38 | 62 |
| Selling, general & admin | 174 | 139 | 100 | 107 | 107 |
| Operating income | (265) | (81) | (46) | (50) | 23 |
| Pre-tax income | (282) | (94) | (52) | (69) | (3.7) |
| Income tax | 0 | 0 | 0 | 0 | 1.6 |
| Net income | (282) | (94) | (52) | (69) | (5.3) |
| Diluted EPS | −$1.70 | −$0.52 | −$0.28 | −$0.33 | −$0.02 |
| Diluted shares (millions) | 166 | 183 | 187 | 211 | 257 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
−12.49 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
6/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 5, 2026